LAY
N-acetyl-L-leucine
| Created: | 2015-01-22 |
| Last modified: | 2024-09-27 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 27 |
| Chiral Atom Count | 1 |
| Bond Count | 26 |
| Aromatic Bond Count | 0 |
Chemical Component Summary | |
|---|---|
| Name | N-acetyl-L-leucine |
| Systematic Name (OpenEye OEToolkits) | (2S)-2-acetamido-4-methyl-pentanoic acid |
| Formula | C8 H15 N O3 |
| Molecular Weight | 173.21 |
| Type | L-PEPTIDE LINKING |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | O=C(NC(C(=O)O)CC(C)C)C |
| SMILES | CACTVS | 3.385 | CC(C)C[CH](NC(C)=O)C(O)=O |
| SMILES | OpenEye OEToolkits | 1.7.6 | CC(C)CC(C(=O)O)NC(=O)C |
| Canonical SMILES | CACTVS | 3.385 | CC(C)C[C@H](NC(C)=O)C(O)=O |
| Canonical SMILES | OpenEye OEToolkits | 1.7.6 | CC(C)C[C@@H](C(=O)O)NC(=O)C |
| InChI | InChI | 1.03 | InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1 |
| InChIKey | InChI | 1.03 | WXNXCEHXYPACJF-ZETCQYMHSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB16956 |
|---|---|
| Name | L-Acetylleucine |
| Groups |
|
| Description | Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo.[A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine, after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to the racemic mixture.[A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444] |
| Synonyms |
|
| Brand Names |
|
| Indication | Levacetylleucine is indicated for the treatment of neurological symptoms of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.[L51439] |
| Categories |
|
| CAS number | 1188-21-2 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Solute carrier family 22 member 6 | MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR... | unknown | substrate,inhibitor |
| Organic anion transporter 3 | MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR... | unknown | substrate,inhibitor |
| ATP-dependent translocase ABCB1 | MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY... | unknown | inhibitor |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS... | unknown | inhibitor |
| Bile salt export pump | MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQL... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| PubChem | 70912 |
| ChEMBL | CHEMBL56021 |
| ChEBI | CHEBI:17786 |
| CCDC/CSD | ACLLEU01 |














